Aurobindo Pharma gets USFDA ok for DM suspension 2026

What the USFDA approval is for

Aurobindo Pharma has received US Food and Drug Administration approval for dextromethorphan polistirex extended-release oral suspension, according to a Reuters report dated April 17, 2026 (09:04 am EDT). The update adds another US regulatory clearance to the company’s portfolio of respiratory and cough-related products referenced across the provided material. Dextromethorphan is commonly used as a cough suppressant, and the “extended-release” format typically implies longer duration of action per dose. The information shared in the feed does not specify the brand reference product, dosage strength, or expected launch timing for this specific suspension. It also does not include sales contribution guidance or commercial terms. Still, USFDA approvals are closely tracked for Indian drugmakers because the US is a key generic market.

Source and timing of the disclosure

The approval update is attributed to Reuters and marked as published on 04/17/2026. No additional management commentary or direct quote is included in the excerpt. The text provided also shows market reference points, including the stock’s last close price and an average target price. Those datapoints help frame how the market may be benchmarking the company at the time the approval is reported. Beyond the approval itself, the feed includes multiple US label and product listing snippets that link Aurobindo entities to cough and expectorant combinations.

How this fits into Aurobindo’s cough and cold product set

Alongside the suspension approval headline, the material contains detailed label references for OTC cough-relief products that include guaifenesin and dextromethorphan HBr in extended-release tablet form. One label referenced is “MUCUS RELIEF DM” described as an extended-release tablet containing 600 mg guaifenesin and 30 mg dextromethorphan HBr, positioned as an “Expectorant & Cough Suppressant” with “12 HOUR” duration. The listed uses include loosening phlegm, thinning bronchial secretions, and temporary relief of cough related to minor throat and bronchial irritation. The label content also notes relief of the intensity of coughing and the impulse to cough to help with sleep.

Manufacturing and label references mentioned in the text

The provided label excerpts include multiple NDC codes and packager information. For “MUCUS RELIEF DM”, NDC codes shown include 49035-960-12 and 49035-960-73, with Wal-Mart Stores, Inc. identified as the packager in that section. The same text also states that MUCUS RELIEF DM is an OTC medication “manufactured, distributed, or labeled by Better Living Brands LLC, Aurohealth LLC, Aurobindo Pharma Limited.”

A separate entry lists: “GUAIFENESIN AND DEXTROMETHORPHAN HBR tablet, extended release” with an NDC code shown as 58602-871-83, and the packager as Aurohealth LLC. The label section reiterates the active ingredients per tablet: Dextromethorphan Hydrobromide USP 30 mg and Guaifenesin USP 600 mg, with purposes listed as cough suppressant and expectorant. These label references are distinct from the Reuters headline about dextromethorphan polistirex extended-release oral suspension, but they indicate activity in adjacent cough and cold categories.

Earlier USFDA approvals referenced: tablets and asthma treatment

The text also includes an earlier company statement about USFDA final approval to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets in 600/30 mg and 1200/60 mg strengths. That filing described the product as a generic version of Reckitt Benckiser’s Mucinex DM cough relief tablets. It added that the tablets would be launched in the first quarter of 2017-18, and cited IRI data estimating a USD 235 million market size for the 12 months ended December 2016.

Separately, the material references Aurobindo’s subsidiary receiving approval to market a generic medication to treat asthma in children, with mention of Budesonide inhalation suspension. It also references a sequence where this nod came a day after another US regulator nod to market a generic medication for HIV-1 infection, but the excerpt does not provide product names, ANDA numbers, or launch plans for those items.

Stock and reference details shown alongside the item

The feed lists Last Close Price: 1,386.50 INR and Average target price: 1,379.96 INR. It also contains a compliance officer record with the name Shrikant Jagtap and an email address and phone number, plus an address in Pune, Maharashtra (411045). These appear as reference details included with the item, although they are not directly linked to the USFDA approval announcement in the excerpt.

Key facts snapshot

Market impact: what investors typically track from such approvals

USFDA approvals matter because they can expand the set of products a company can supply to the US market, but the commercial impact depends on details not present in the excerpt. Investors generally look for clarity on whether an approval is final, whether the product is first-to-file or has limited competition, and when shipments could begin. In this case, the Reuters headline confirms the approval but does not provide a launch date or addressable market size for the dextromethorphan polistirex suspension. The only explicit market size number in the provided material relates to the older cough-tablet approval, cited at USD 235 million for a 12-month period ending December 2016.

Analysis: why the suspension approval still matters

The approval is notable because it signals continued progress on US regulatory clearances for Aurobindo, and it aligns with multiple cough and respiratory-related product references in the text. The presence of label entries that name Aurobindo Pharma Limited in “ANALYSIS” and “MANUFACTURE” operations suggests manufacturing linkages for certain listed products, although the excerpt does not map those entries directly to the newly approved suspension. The combination of an approval headline plus multiple related label snippets underscores how cough and cold categories can span both prescription-style ANDA pathways and OTC label listings. For readers tracking regulatory momentum, this item is another data point, but the financial relevance cannot be quantified from the provided excerpt alone.

Conclusion

Aurobindo Pharma’s reported USFDA approval for dextromethorphan polistirex extended-release oral suspension adds to a stream of US-facing respiratory and cough-related regulatory references present in the material. The update was published by Reuters on April 17, 2026, while the stock reference data alongside the item lists a last close of 1,386.50 INR and an average target price of 1,379.96 INR. Further clarity on launch timing and market sizing for the newly approved suspension would typically come from subsequent company disclosures.